https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42632 Wed 31 Aug 2022 10:51:48 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:54364 Wed 28 Feb 2024 15:25:51 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:45282 Wed 26 Oct 2022 20:12:03 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48372 Wed 15 Mar 2023 13:33:38 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36891 Wed 15 Jul 2020 12:45:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36890 Wed 15 Jul 2020 12:45:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27199 Wed 11 Apr 2018 17:09:32 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27206 Wed 11 Apr 2018 17:06:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27169 Wed 11 Apr 2018 16:29:20 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27201 Wed 11 Apr 2018 16:20:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27230 Wed 11 Apr 2018 16:19:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27229 Wed 11 Apr 2018 15:03:15 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27204 Wed 11 Apr 2018 14:38:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27198 Wed 11 Apr 2018 14:24:41 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27205 Wed 11 Apr 2018 13:32:27 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27202 Wed 11 Apr 2018 13:27:19 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27192 5 decreased by 2.6% (3.7–1.1%); and abnormal bleeds fell by 1.2% (1.2–0%). Conclusion: This multifaceted suite of interventions was successful in influencing clinician behaviour and improving compliance with evidence-based warfarin guidelines.]]> Wed 11 Apr 2018 12:38:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27207 Wed 11 Apr 2018 12:31:34 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27195 Wed 11 Apr 2018 12:06:12 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27196 Wed 11 Apr 2018 10:54:04 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27194 Wed 11 Apr 2018 10:34:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27231 Wed 11 Apr 2018 10:25:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27197 Wed 11 Apr 2018 10:03:16 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27203 Wed 11 Apr 2018 09:53:52 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:38930 Wed 09 Mar 2022 12:20:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32458 Wed 06 Jun 2018 11:37:13 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:34097 Wed 04 Sep 2019 12:18:51 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48583 Tue 21 Mar 2023 18:09:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39846 Tue 19 Jul 2022 08:50:10 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41970 Tue 16 Aug 2022 15:06:21 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46982 Tue 13 Dec 2022 09:00:17 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36562 Tue 09 Jun 2020 12:53:09 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33894 Tue 03 Sep 2019 18:02:17 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27193 Tue 03 Sep 2019 17:58:02 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50678 Tue 01 Aug 2023 15:33:58 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:33699 Thu 28 Sep 2023 15:17:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43138 Thu 28 Sep 2023 13:22:49 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48725 Thu 22 Aug 2024 11:08:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:42084 Thu 18 Aug 2022 11:14:08 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:31532 Sat 24 Mar 2018 08:43:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27200 Sat 24 Mar 2018 07:31:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26639 Sat 24 Mar 2018 07:26:57 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48169 Sat 11 Mar 2023 12:22:50 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48676 P < 0.001). Internal consistency of the total six PCC-36 functions was confirmed by a Cronbach’s alpha of 0.97. Conclusions: The study proved that the PCC-36 Arabic version is a valid and reliable instrument for the measurement of patient communication experiences in cancer care in Saudi Arabia, with similar properties to the original, and that this instrument may be used in 22 different Arab countries to measure and improve cancer patients’ communication experiences.]]> Mon 27 Mar 2023 14:25:49 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26663 Mon 26 Aug 2024 15:31:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:44778 Mon 24 Oct 2022 09:10:26 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26638 TM glenoid component. Method: A radiologic and clinical evaluation of the second-generation TM glenoid was conducted in consecutive cases of 76 shoulders (66 patients) with a mean follow-up of 43.2 months (range 24-72 months). Pre-operative VAS score, patient self-assessed ASES score, active shoulder range of motion, and radiologic assessment were recorded. Patients were recalled for latest follow-up clinical and radiologic evaluation. Results: On latest follow-up, the mean VAS scores (pre-op: 6.4-latest: 0.9) and ASES scores (pre-op: 36.9-latest: 88.5) improved. Active range of motion improved in all planes. There was no report of glenoid component migration, loosening, or humeral stem subsidence. The incidence of non-progressive radiolucency in the glenoid was 6.6 % (Franklin 1: 3 cases, Franklin 2: 2 cases). Post-operative complications involved dislocation (n = 2) which were reduced in ED, post-operative stiffness (n = 1), transient axillary nerve neuropraxia (n = 1), and supraspinatus tear which underwent arthroscopic repair at 16 months post-op. There were no revision surgeries for implant loosening nor glenoid component fracture at the peg-base plate junction. Conclusions: The modifications established in the second-generation TM glenoid resulted to improve early to mid-term survivorship and clinical outcomes in TSR, with promise of long-term implant stability through bony ingrowth. Level of evidence: Level IV, case series, treatment study.]]> Mon 23 Sep 2019 13:49:24 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48510 Care4myHeart. Objective: This research aimed to determine patient experiences of using the app to self-manage heart failure. Methods: Patients with heart failure used the app for 14 days on their own smart device in a home setting, following which a mixed-methods evaluation was performed. Eight patients were recruited, of whom six completed the Mobile Application Rating Scale and attended an interview. Results: The overall app quality score was “acceptable” with 3.53 of 5 points, with the aesthetics (3.83/5) and information (3.78/5) subscales scoring the highest. The lowest mean score was in the app-specific subscale representing the perceived impact on health behavior change (2.53/5). Frequently used features were weight and fluid restriction tracking, with graphical representation of data particularly beneficial for improved self-awareness and ongoing learning. The use of technology for self-management will fundamentally differ from current practices and require a change in daily routines. However, app use was correlated with potential utility for daily management of illness with benefits of accurate recording and review of personal health data and as a communication tool for doctors to assist with care planning, as all medical information is available in one place. Technical considerations included participants’ attitudes toward technology, functionality and data entry issues, and relatively minor suggested changes. Conclusions: The findings from this usability study suggest that a significant barrier to adoption is the lack of integration of technology into everyday life in the context of already established disease self-management routines. Future studies should explore the barriers to adoption and sustainability of consumer mobile health interventions for chronic conditions, particularly whether introducing such apps is more beneficial at the commencement of a self-management regimen.]]> Mon 20 Mar 2023 16:25:46 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:51534 Mon 18 Sep 2023 14:15:55 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:39140 Mon 16 May 2022 15:34:35 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:32063 Fri 27 Apr 2018 09:25:50 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:26655 Fri 24 May 2019 12:30:43 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27086 Fri 24 May 2019 12:30:11 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27085 40 medical patients each year were targeted to receive the intervention which consisted of a one-to-one educational visit on VTE prevention from a trained peer facilitator. The EOV protocol was designed by a multidisciplinary group of healthcare professionals using social marketing theory. Results: Nineteen (73%) of 26 eligible participants received an EOV. The majority (n = 16, 85%) felt the EOV was effective or extremely effective at increasing their knowledge about VTE prophylaxis and 15 (78%) gave a verbal commitment to provide evidence-based prophylaxis. The average length of each visit was 15 minutes (IQ range 15 to 20) and the average time spent arranging and conducting each visit was 92 minutes (IQ range 78 to 129). There was a significant improvement in the proportion of medical patients receiving appropriate pharmacological VTE prophylaxis following the intervention (54% to 70%, 16% improvement, 95% CI 5 to 26, p = 0.004). Conclusions: EOV is effective at improving doctors’ provision of pharmacological VTE prophylaxis to hospitalised medical patients. It was also found to be an acceptable implementation strategy by the majority of participants; however, it was resource intensive requiring on average 92 minutes per visit.]]> Fri 24 May 2019 12:29:42 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27087 Fri 24 May 2019 12:28:47 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35154 Fri 21 Jun 2019 14:59:03 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:35156 Fri 21 Jun 2019 14:59:02 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37575 Fri 19 Feb 2021 15:37:52 AEDT ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50543 Fri 18 Aug 2023 11:51:37 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:43396 Fri 16 Sep 2022 09:58:32 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:27082 Fri 13 Jul 2018 15:56:32 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:41822 Fri 12 Aug 2022 12:52:22 AEST ]]> https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:53593 Fri 08 Dec 2023 15:53:13 AEDT ]]>